Danny Rischin - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Danny Rischin's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Danny Rischin
Verified
Associate Editor, Journal of Global Oncology
Melbourne
Beats
that, cover, there's, we, don't, nothing
Content
"High Response Rate With Extended Dosing of Cemiplimab in Advanced Cuta" by Danny Rischin, Brett G M Hughes et al.
By Danny Rischin, Nicole Basset-Seguin, Dirk Schadendorf, Samantha Bowyer| Texas Medical Center@ BACKGROUND: Cemiplimab (LibtayoMETHODS: In this open-label, phase II trial (ClinicalTrials.gov identifier NCT02760498), the cohort of patients ≥18 years old with advanced CSCC received cemiplimab 600 mg intravenously Q4W for up to 48 weeks. Tumor measurements were recorded every 8 weeks. The primary endpoint was objective response rate by independent central review. RESULTS: Sixty-three patients with advanced CSCC were treated with cemiplimab.
By Danny Rischin, Nicole Basset-Seguin, Dirk Schadendorf, Samantha Bowyer| bmj.com@ Clinical/translational cancer immunotherapy High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma Statistics from Altmetric.com Request Permissions If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
"High Response Rate With Extended Dosing of Cemiplimab in Advanced Cuta" by Danny Rischin, Brett G M Hughes et al.
By Danny Rischin, Nicole Basset-Seguin, Dirk Schadendorf, Samantha Bowyer| Texas Medical Center@ BACKGROUND: Cemiplimab (LibtayoMETHODS: In this open-label, phase II trial (ClinicalTrials.gov identifier NCT02760498), the cohort of patients ≥18 years old with advanced CSCC received cemiplimab 600 mg intravenously Q4W for up to 48 weeks. Tumor measurements were recorded every 8 weeks. The primary endpoint was objective response rate by independent central review. RESULTS: Sixty-three patients with advanced CSCC were treated with cemiplimab.
Company Info
Journal of Global Oncology
Melbourne, Victoria, Australia
+61 3 8559 5000